glycine has been researched along with Basal Ganglia Diseases in 3 studies
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 5.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| "Glycine was administered in an effort to facilitate endogenous glutamatergic transmission at the level of the N-methyl-D-aspartate (NMDA) receptor complex, since a glutamatergic deficiency in the pathophysiology of schizophrenia has been postulated." | 1.28 | Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. ( Banay-Schwartz, M; Cohen, CG; Deutsch, SI; Leighton, M; Rosse, RB; Scarcella, E; Theut, SK, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rohman, MS | 1 |
| Koga, Y | 1 |
| Takano, K | 1 |
| Chon, H | 1 |
| Crouch, RJ | 1 |
| Kanaya, S | 1 |
| Ohnuma, T | 1 |
| Sakai, Y | 1 |
| Maeshima, H | 1 |
| Higa, M | 1 |
| Hanzawa, R | 1 |
| Kitazawa, M | 1 |
| Hotta, Y | 1 |
| Katsuta, N | 1 |
| Takebayashi, Y | 1 |
| Shibata, N | 1 |
| Arai, H | 1 |
| Rosse, RB | 1 |
| Theut, SK | 1 |
| Banay-Schwartz, M | 1 |
| Leighton, M | 1 |
| Scarcella, E | 1 |
| Cohen, CG | 1 |
| Deutsch, SI | 1 |
3 other studies available for glycine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Effect of the disease-causing mutations identified in human ribonuclease (RNase) H2 on the activities and stabilities of yeast RNase H2 and archaeal RNase HII.
Topics: Amino Acid Sequence; Basal Ganglia Diseases; Circular Dichroism; Enzyme Stability; Glycine; Humans; | 2008 |
No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Alanine; Antipsychotic Agents; Basal Ganglia Diseases; Biomarkers; Brief Ps | 2012 |
Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study.
Topics: Adjuvants, Pharmaceutic; Adult; Aged; Basal Ganglia Diseases; Benztropine; Chronic Disease; Cognitio | 1989 |